Canaccord Genuity began coverage on shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in a research report issued on Friday. The brokerage set a “buy” rating and a $35.00 price target on the stock. Canaccord Genuity’s price target would indicate a potential upside of 55.07% from the stock’s previous close.
Several other equities analysts have also recently weighed in on VYGR. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. ValuEngine cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Stifel Nicolaus initiated coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $28.75.
Voyager Therapeutics (VYGR) opened at 22.57 on Friday. The stock’s market cap is $607.20 million. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $25.99. The stock has a 50 day moving average of $19.75 and a 200 day moving average of $12.18.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Equities analysts anticipate that Voyager Therapeutics will post ($2.87) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.com-unik.info/2017/10/29/voyager-therapeutics-inc-vygr-coverage-initiated-at-canaccord-genuity.html.
In related news, insider Bernard Ravina sold 10,980 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $20.33, for a total value of $223,223.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 32,940 shares of company stock valued at $490,092 over the last three months. 8.00% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its holdings in Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after acquiring an additional 4,343 shares in the last quarter. Hershey Trust Co. increased its holdings in Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after acquiring an additional 8,921 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Voyager Therapeutics in the 2nd quarter worth approximately $143,000. Rhumbline Advisers increased its holdings in Voyager Therapeutics by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after acquiring an additional 4,144 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Voyager Therapeutics by 8.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares in the last quarter. 40.74% of the stock is owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
What are top analysts saying about Voyager Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Voyager Therapeutics Inc. and related companies.